Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease

American Journal of Nephrology

Volumn 32, Issue 5, 2010, Pages 425-431

  Fürstenberg, Antje ^a   Buscombe, John ^b   Davenport, Andrew ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic kidney disease; Dialysis; Dual energy X ray absorptiometry; Lanthanum carbonate; Phosphate binder

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM PHOSPHATE; CINACALCET; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARM; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM BONE LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEMODIALYSIS; HIP; HUMAN; HYPERPHOSPHATEMIA; LEG; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; PARATHYROID HORMONE BLOOD LEVEL; PELVIS; PERITONEAL DIALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RIB; SCORING SYSTEM; THORACIC SPINE;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; DIAGNOSTIC ERRORS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 77956803843     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320481     Document Type: Article

References (22)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calciumx phosphate product with mortality risk in chronic haemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
2. Sugisaki H, Onohara M, Kunitomo T: Dynamic behavior of plasma phosphate in chronic dialysis patients. Trans Am Soc Artif Intern Organs 1982;28:302-307.
3. Davenport A, Gardner C, Delaney M, Pan Thames Renal Audit Group: The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010;25:897-901.
4. Morey B, Walker R, Davenport A: More dietetic time, better outcome? A randomized prospective study investigating the effect of more dietetic time on phosphate control in end-stage kidney failure haemodialysis patients. Nephron Clin Pract 2008;109:c173-c180.
5. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. www.kidney.org/professionals/kdoqi/guidelines-bone/ index.htm.
6. Renal Association Clinical Practice Guidelines, ed 4. Module 2, Complications. 2007. www.renal.org/guidelines.
7. Jones G, Kingdon E, Sweny P, Davenport A: Tumoral calcinosis and calciphylaxis presenting in a dialysis patient. Nephrol Dial Transplant 2003;18:2668-2670.
8. Davenport A, Newton KE, Toothill C, Will EJ, Davison AM: Effect of aluminum mobilization on hemoglobin during the first six months after transplantation. Kidney Int 1993;43:1313-1318.
9. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN: Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminium. Lancet 1978;1:841-845.
10. Davenport A, Goel S, MacKenzie JC: Audit of the use of calcium carbonate as a phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1992;7:632-635.
11. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
12. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D'Haese PC: Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21:2217-2224.
13. Hutchinson AJ, Barnett ME, Krause R, Kwan JT, Siami GA, SPD405-309 Lanthanum Study Group: Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008;110: c15-c23.
14. LeBlanc AD, Schneider VS, Engelbretson DA, Evans HJ: Precision of regional bone mineral measurements obtained from totalbody scans. J Nucl Med 1990:31:43-45.
15. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000;13:437-443.
16. Lohman M, Tallroth K, Kettunen JA, Marttinen MT: Reproducibility of dual-energy X-ray absorptiometry total and regional body composition measurements using different scanning positions and definitions of regions. Metabolism 2009;58:1663-1668.
17. Syed Z, Khan A: Bone densitometr y: applications and limitations. J Obstet Gynaecol Can 2002;24:476-484.
18. Santos RD, Rumberger JA, Budoff MJ, Shaw LJ, Orakzai SH, Berman D, Raggi P, Blumenthal RS, Nasir K: Thoracic aorta calcification detected by electron beam tomography predicts all-cause mortality. Atherosclerosis 2010;209:131-135.
19. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG: Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008;23:586-593.
20. Davenport A, Gardner C, Delaney M: Do differences in dialysis prescription impact on KDOQI bone mineral targets? The Pan Thames Renal Audit. Blood Purif 2010;30:111-117.
21. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodia lysis. J Nephrol 2000;13:437-443.
22. Pennick M, Dennis K, Damment SJ: Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006;46:738-746.